Saga Investments LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Saga Investments LLC
Finance Watch: Mega-Round Mania As RNA Therapeutics, Gene Editing Attract VC Cash
Private Company Edition: Two companies raised multiple hundreds of millions of dollars each helping to keep the number of $100m-plus venture capital mega-rounds on the rise in May. Also, Ascend raised $132.5m to make gene and cell therapies, and Nido emerged with $109m for neurological diseases.
Quidel Subsidiary Lands First De Novo Clearance For COVID-19 Serology Tests
VITROS COVID-19 tests from Ortho-Clinical Diagnostics have been cleared by the US FDA, establishing regulatory pathway for future similar tests.
Gilead Waives Acquisition Option As Pionyr Explores Other Strategies
Gilead has waived its option to acquire Pionyr, allowing the US biotech to explore other partnerships and financing opportunities as it advances a promising pipeline of macrophage-targeting antibodies.
Biopharma Industry Sharply Divided Over Supreme Court Antibody Patent Brawl
Big biologic makers line up on opposite sides of dispute between Amgen and Sanofi over whether Amgen’s Repatha patents cover analogous antibodies with the same functional characteristics.
- Other Names / Subsidiaries
- deCODE genetics ehf
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.